Coherus BioSciences is now heavily focused on developing its pipeline, particularly casdozokitug and CHS-114. See why I rate ...

– Coherus to focus exclusively on its innovative novel oncology programs including: – LOQTORZI®, a revenue-generating and differentiated PD-1 inhibitor; – Casdozokitug, a first-in-class interleukin-27 ...

[indiscernible] recently highlighted that not all PD-1 inhibitors are the same in a review ... a IL-27 antagonist in CHS-114, a cytolytic CCR8 antibody, are designed to deliver data this year ...

CCR8 is a chemokine receptor enriched on immunosuppressive ... Earlier this year, vopratelimab in combination with PD-1 inhibitor pimivalimab failed to outperform pimivalimab alone in the phase ...

today announced that an abstract highlighting interim data from its ongoing Phase 1 clinical trial evaluating CHS-114, a selective, cytolytic anti-CCR8 antibody, as monotherapy and in combination ...

Data to be presented on ABBV-514, a novel CCR8 targeting antibody, in Phase 1 for non-small cell lung cancer, head and neck cancer and other solid tumors. Other presentations highlight key ...

Coherus to focus exclusively on its innovative novel oncology programs including:– LOQTORZI®, a revenue-generating and differentiated PD-1 ... anti-CCR8 antibody currently in Phase 1 studies ...

today announced that an abstract highlighting interim data from its ongoing Phase 1 clinical trial evaluating CHS-114, a selective, cytolytic anti-CCR8 antibody, as monotherapy and in combination ...